For example, the efficacy of agents targeting AR co-regulators and pioneer factors (transcription factors that can directly bind and open condensed chromatin to activate gene expression) that are active in epithelial cells and not fibroblasts/CAFs (e.g., FOXA1) is currently being investigated for the treatment of advanced prostate cancer [268,269,270]. The gene discussed is AR; the disease is prostate carcinoma.